EP3538078A4 - Formulations pour administration efficace de cannabinoïdes - Google Patents

Formulations pour administration efficace de cannabinoïdes Download PDF

Info

Publication number: EP3538078A4
Authority: EP; European Patent Office
Prior art keywords: cannabinoids; formulas; efficient administration; administration; efficient
Prior art date: 2016-11-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17869632.4A

Other languages

German (de)

English (en)

Other versions

EP3538078A1 (fr

Inventor

Benjamin F. Ross

Jerry B. Gin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Gin Jerry B

Bennes Inc

Original Assignee

Gin Jerry B

Bennes Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-11

Filing date

2017-11-11

Publication date

2020-07-08

2017-11-11 Application filed by Gin Jerry B, Bennes Inc filed Critical Gin Jerry B

2019-09-18 Publication of EP3538078A1 publication Critical patent/EP3538078A1/fr

2020-07-08 Publication of EP3538078A4 publication Critical patent/EP3538078A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Natural Medicines & Medicinal Plants (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Alternative & Traditional Medicine (AREA)
Mycology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medical Informatics (AREA)
Botany (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Physiology (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP17869632.4A 2016-11-11 2017-11-11 Formulations pour administration efficace de cannabinoïdes Withdrawn EP3538078A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662420981P	2016-11-11	2016-11-11
PCT/US2017/061202 WO2018089863A1 (fr)	2016-11-11	2017-11-11	Formulations pour administration efficace de cannabinoïdes

Publications (2)

Publication Number	Publication Date
EP3538078A1 EP3538078A1 (fr)	2019-09-18
EP3538078A4 true EP3538078A4 (fr)	2020-07-08

Family

ID=62110287

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17869632.4A Withdrawn EP3538078A4 (fr)	2016-11-11	2017-11-11	Formulations pour administration efficace de cannabinoïdes

Country Status (3)

Country	Link
EP (1)	EP3538078A4 (fr)
CA (1)	CA3046638A1 (fr)
WO (1)	WO2018089863A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10596131B2 (en)	2017-11-22	2020-03-24	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en)	2017-12-19	2020-03-24	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10736861B2 (en)	2016-03-11	2020-08-11	Axcess Global Sciences, Llc	Mixed salt compositions for producing elevated and sustained ketosis
US11241403B2 (en)	2016-03-11	2022-02-08	Axcess Global Sciences, Llc	Beta-hydroxybutyrate mixed salt compositions and methods of use
US10973786B2 (en)	2016-03-11	2021-04-13	Axcess Global Sciences, Llc	R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245242B1 (en)	2017-11-22	2019-04-02	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en)	2017-12-19	2019-04-02	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596129B2 (en)	2017-11-22	2020-03-24	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en)	2017-12-19	2021-11-30	Axcess Global Sciences, Llc	S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973792B2 (en)	2019-02-13	2021-04-13	Axcess Global Sciences, Llc	Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11103470B2 (en)	2017-11-22	2021-08-31	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12329734B2 (en)	2017-12-19	2025-06-17	Axcess Global Sciences, Llc	Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12496283B2 (en)	2016-04-19	2025-12-16	Axcess Global Sciences, Llc	Administration of R-beta-hydroxybutyrate and related compounds in humans
US10925843B2 (en)	2018-04-18	2021-02-23	Axcess Global Sciences, Llc	Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en)	2017-11-22	2021-12-21	Axcess Global Sciences, Llc	Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12109182B2 (en)	2016-04-19	2024-10-08	Axcess Global Sciences, Llc	Administration of R-beta-hydroxybutyrate and related compounds in humans
US11944598B2 (en)	2017-12-19	2024-04-02	Axcess Global Sciences, Llc	Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11806324B2 (en)	2018-04-18	2023-11-07	Axcess Global Sciences, Llc	Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10239808B1 (en)	2016-12-07	2019-03-26	Canopy Holdings, LLC	Cannabis extracts
AU2018333282A1 (en) *	2017-09-15	2020-03-19	Zelira Therapeutics Operations Pty Ltd	Composition and method for treating autism
US12090129B2 (en)	2017-11-22	2024-09-17	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11202771B2 (en)	2018-01-31	2021-12-21	Treehouse Biotech, Inc.	Hemp powder
US20200061023A1 (en) *	2018-08-27	2020-02-27	Axcess Global Sciences, Llc	Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en)	2019-02-13	2022-08-23	Axcess Global Sciences, Llc	Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en)	2020-02-06	2022-02-08	Axcess Global Sciences, Llc	Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en)	2018-08-27	2021-09-28	Axcess Global Sciences, Llc	Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en)	2018-08-27	2021-04-20	Axcess Global Sciences, Llc	Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
CN108703963B (zh) *	2018-07-02	2023-04-14	宁夏医科大学	茴香脑在制备治疗神经病理性疼痛药物中的用途
US20210299202A1 (en) *	2018-07-10	2021-09-30	Cardinal Advisory Limited	Formulation of cannabinoid compounds
JP2021535195A (ja) *	2018-08-07	2021-12-16	アイエルワイエルティー・エルエルシーIlylt, Llc	性機能障害を治療し性的反応と快感を増強するための組成物および方法
EP3864000A4 (fr)	2018-10-10	2022-08-10	Treehouse Biosciences, Inc.	Synthèse du cannabigérol
CN109758450B (zh) *	2019-03-06	2021-01-29	天津医科大学	一种抗肿瘤新化合物、及其制备方法和用途
US20200323935A1 (en) *	2019-04-10	2020-10-15	G.I. Pharmaceuticals, Inc. dba E2BIO CONSULTANTS, INC.	Novel method for the treatment of dyspepsia, food and medicine intolerances, irritable bowel syndrome and other functional gastrointestinal conditions
CA3040547C (fr) *	2019-04-17	2021-12-07	Medcan Pharma A/S	Formulation de pastille de cannabinoide
US11633351B2 (en)	2019-12-13	2023-04-25	Nordiccan A/S	Fast disintegrating cannabinoid tablets
US10925853B2 (en)	2019-04-17	2021-02-23	Nordiccan A/S	Oral cannabinoid tablet
CA3040532C (fr) *	2019-04-17	2021-12-21	Medcan Pharma A/S	Pastille pour administration amelioree de cannabinoides
US12472200B2 (en)	2019-05-15	2025-11-18	Axcess Global Sciences, Llc	Autobiotic compositions and method for promoting healthy gut microbiome
US11969430B1 (en)	2023-03-10	2024-04-30	Axcess Global Sciences, Llc	Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en)	2019-06-21	2024-12-17	Axcess Global Sciences, Llc	Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en)	2019-06-21	2021-06-15	Axcess Global Sciences, Llc	Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en)	2019-06-21	2024-04-09	Axcess Global Sciences, Llc	Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12274690B2 (en) *	2019-07-08	2025-04-15	Aaron Miles	System and method for incorporating CBD/THC cannabinoid nanoparticle carrier compositions into particulate foods and food additives
WO2021030190A1 (fr) *	2019-08-09	2021-02-18	Jupiter Wellness, Inc.	Formulations de cbd et leurs utilisations
WO2021195540A1 (fr) *	2020-03-26	2021-09-30	Radient Technologies Innovations Inc.	Composition à base de cannabinoïdes pour l'atténuation d'effets viraux
SE544672C2 (en) *	2020-05-07	2022-10-11	Liw Innovation Ab	New compositions for oral or nasal use
US12186297B2 (en)	2020-08-26	2025-01-07	Axcess Global Sciences, Llc	Compositions and methods for increasing lean-to-fat mass ratio
WO2022189432A1 (fr) *	2021-03-09	2022-09-15	Nutrition & Biosciences Usa 1, Llc	Composition d'oléogel comprenant une éthylcellulose et un ingrédient actif huileux
WO2023114529A2 (fr) *	2021-12-17	2023-06-22	Bennes, Inc.	Formulations pharmacoactives pour administration de composés psychédéliques
GB2632418A (en) *	2023-08-04	2025-02-12	Anthony Neish Jason	Oral compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060039959A1 (en) *	2002-06-14	2006-02-23	Werner Wessling	Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents
US20060257463A1 (en) *	2002-05-31	2006-11-16	University Of Mississippi	Transmucosal delivery of cannabinoids
WO2015200864A1 (fr) *	2014-06-27	2015-12-30	Crowley Kenton L	Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090081294A1 (en) *	2007-09-26	2009-03-26	Gin Jerry B	Sustained release dosage form for lubricating an oral cavity
JP5704925B2 (ja) *	2008-02-08	2015-04-22	ウェルズファーゴバンクナショナルアソシエイション	オリゴマー−カンナビノイドコンジュゲート
US9186386B2 (en) *	2014-04-17	2015-11-17	Gary J. Speier	Pharmaceutical composition and method of manufacturing

2017
- 2017-11-11 EP EP17869632.4A patent/EP3538078A4/fr not_active Withdrawn
- 2017-11-11 WO PCT/US2017/061202 patent/WO2018089863A1/fr not_active Ceased
- 2017-11-11 CA CA3046638A patent/CA3046638A1/fr not_active Abandoned

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060257463A1 (en) *	2002-05-31	2006-11-16	University Of Mississippi	Transmucosal delivery of cannabinoids
US20060039959A1 (en) *	2002-06-14	2006-02-23	Werner Wessling	Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents
WO2015200864A1 (fr) *	2014-06-27	2015-12-30	Crowley Kenton L	Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018089863A1 *

Also Published As

Publication number	Publication date
EP3538078A1 (fr)	2019-09-18
WO2018089863A1 (fr)	2018-05-17
CA3046638A1 (fr)	2018-05-17

Publication	Publication Date	Title
EP3538078A4 (fr)	2020-07-08	Formulations pour administration efficace de cannabinoïdes
EP3493799A4 (fr)	2020-04-01	Composition pharmaceutique decannabis
DK3386511T3 (da)	2021-07-05	Fremgangsmåder til behandling af huntingtons sygdom
EP3503875C0 (fr)	2025-09-17	Compositions hydrosolubles comprenant des cannabinoïdes purifiés
IL247262A0 (en)	2016-09-29	Cannabinoid compositions and uses
IL264143B (en)	2021-10-31	Processes for preparing olaparib
EP3513809A4 (fr)	2020-06-03	Composition médicinale
LT3206715T (lt)	2020-09-25	Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui
EP3493798A4 (fr)	2020-05-06	Composition pharmaceutique decannabis
EP3454899C0 (fr)	2024-03-20	Composition pharmaceutique
DK3237045T3 (da)	2021-05-10	Indretning til indgivelse af lægemidler
DK3503890T3 (da)	2025-01-27	Anvendelse af pridopidin til behandling af dystonier
DK3558278T3 (da)	2021-08-09	Flydende cannabinoidsammensætning
EP3424940A4 (fr)	2019-10-30	Médicament radiomarqué
EP3731832A4 (fr)	2021-09-15	Forme posologique à base de cannabinoïdes
EP3541200C0 (fr)	2025-09-03	Formulations pulvérulentes
EP3530264A4 (fr)	2020-07-01	Composition d'émulsion de type huile dans l'eau
EP3437644A4 (fr)	2019-11-27	Médicament
IL287119B1 (en)	2023-03-01	Bryostatin compounds and methods of preparing the same
EP3402470A4 (fr)	2019-11-13	Composition pharmaceutique stable
DE102015113307A8 (de)	2017-04-06	Vorrichtung zur Durchtrennung von Gewebeteilen
EP3527216A4 (fr)	2020-04-01	Médicament
EP3459369A4 (fr)	2019-12-11	Composition pharmaceutique utilisant la souchelactobacillus
DE112015002229A5 (de)	2017-06-29	Formulierungen zur Behandlung von Hyperthyreose
EP3596175A4 (fr)	2021-01-13	Nanoparticules pour l'administration d'agents chimiopréventifs

Legal Events

Date	Code	Title	Description
2018-05-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-08-16	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-08-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-09-18	17P	Request for examination filed	Effective date: 20190611
2019-09-18	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-09-18	AX	Request for extension of the european patent	Extension state: BA ME
2020-02-19	DAV	Request for validation of the european patent (deleted)
2020-02-19	DAX	Request for extension of the european patent (deleted)
2020-07-08	A4	Supplementary search report drawn up and despatched	Effective date: 20200609
2020-07-08	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/05 20060101ALI20200603BHEP Ipc: A61K 9/00 20060101AFI20200603BHEP Ipc: A61K 47/38 20060101ALI20200603BHEP Ipc: A61P 25/00 20060101ALI20200603BHEP Ipc: A61K 31/352 20060101ALI20200603BHEP Ipc: A61K 36/185 20060101ALI20200603BHEP Ipc: A61P 25/06 20060101ALI20200603BHEP
2021-08-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-09-08	17Q	First examination report despatched	Effective date: 20210809
2022-06-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2022-07-20	18D	Application deemed to be withdrawn	Effective date: 20220222